Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE)

Roger von Moos, Arnoud J. Templeton, Stefanie Hayoz et al.|Annals of Oncology|2018

Cited by 4